HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Widely Available Unapproved Hangover Remedies Concern US FDA As Encouraging Overindulgence

Agency Warns Seven Firms In Market Offering Myriad Options

Executive Summary

As CFSAN warned seven marketers, supplement products from numerous other businesses advertised as hangover remedies, or as formulations to prevent symptoms associated with overindulgence, remained available to US consumers. Like one business FDA warned, numerous companies are offering OTC intravenous treatments for hangovers, available at locations accepting walk-in or by-appointment customers.

You may also be interested in...



No Regulatory Imprimatur In UK For Scottish Firm’s Hangover Remedy Claim

Bounce Back Drinks sought to establish its bona fides as a registered consumer product provider, but statements referencing ASA, EFSA and MHRA imply the agencies reviewed and approved its product and advertising. Plus, hangover remedy claims are prohibited under UK regulations.

FDA Should Call Last Round For OTC Hangover Indication, Cmte. Suggests

Comments from the Nonprescription Drug and the Drug Safety and Risk Management advisory committees during a joint meeting could push US FDA toward pulling the plug on hangover as a monograph indication.

Temporary Funding For US Agencies Delays $5M For FDA’s Cannabidiols Regulatory Pathway Work

Senate on 29 September was expected to a pass a CR the House passed a week earlier to fund FDA and other federal departments and agencies through 11 December.

Topics

UsernamePublicRestriction

Register

LL1134044

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel